tradingkey.logo

Novartis expects to eliminate US tariff exposure by mid‑2026, CEO tells CNBC

ReutersJan 20, 2026 10:08 AM

- Novartis NOVN.S CEO Vas Narasimhan told CNBC on Tuesday he expects the drugmaker's agreement with the U.S. government and its expanding manufacturing footprint in the country to protect it from potential tariffs.

"We expect to be in a position by middle of this year where we are not really exposed to tariffs, because we're able to produce in the U.S. for the U.S.," Narasimhan said.

He noted the company last year announced $23 billion in manufacturing investments and is progressing those projects to further reduce exposure.

The Swiss drugmaker also has an agreement with the U.S. government that could exempt it from tariffs, Narasimhan said, adding that the company is also "future‑proofed" if its products are subject to levies.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI